JPRN-UMIN000023491已完成未知
A double-blind, randomized, placebo-controlled clinical study to investigate the effect of the beverage containing plant extracts - A clinical study to investigate the effect of the beverage containing plant extracts
Fukuhara Clinic0 个研究点目标入组 150 人开始时间: 2017年9月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
There was a significant difference in primary outcome
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Subjects who have marked impairment of liver, kidney, heart, lung, endocrine, metabolism, nerve, or consciousness, or have DM 2.Subjects who have historical disease of circulatory system disease 3.Subjects who use drugs of glycometabolism, lipidmetabolism, or reducing high blood pressure 4.Subjects who regularly use drugs, health foods, supplements which are suggested causal relationship from the study except who agree to quit taking them 5.Subjects who have allergy related to the test foods 6.Subjects who feel bad mood by blood collection in past 7.Subjects who donated 200 mL or more of blood within a month prior to the study. 8.Subjects who participate in other clinical trials within the last 4 weeks prior to the current study 9.Heavy dinkers or heavy smokers 10.Subjects whose eating habits are extremely irregular 11.Pregnant and lactating female, or who wish to get pregnant during the study period. 12.Subjects who can not agree with preliminary explanation. 13.Subjects who are ineligible due to physician's judgment.
研究者
相似试验
已完成
不适用
A double-blind, randomized, placebo-controlled clinical trial to investigate the effect of the beverage containing plant extract (Ex.no.14154)JPRN-UMIN000016455ew drug research center, Inc.150
进行中（未招募）
1 期
A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumoniaCoronavirus infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001686-36-FRASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE168
尚未招募
2 期
A Clinical Trial to study the efficacy & safety of Colebrookea Oppositifolia (Aceteoside) in acute hepatitis patients.CTRI/2008/091/000090Council of Scientific & Industrial Research200
进行中（未招募）
不适用
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy.EUCTR2006-002525-23-ISF. Hoffmann-La Roche Ltd480
进行中（未招募）
1 期
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy.EUCTR2006-002525-23-GBF. Hoffmann-La Roche Ltd480